

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 15

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number: 001-36686

Forward Pharma A/S

(Exact name of registrant as specified in its charter)

**Østergade 24A, 1st Floor
1100 Copenhagen K, Denmark
Tel: +45 3344 4242**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Ordinary shares, nominal value DKK 0.01 per share
American Depositary Shares, each representing 14 ordinary shares**
(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	<input checked="" type="checkbox"/>
Rule 12g-4(a)(2)	<input type="checkbox"/>
Rule 12h-3(b)(1)(i)	<input checked="" type="checkbox"/>
Rule 12h-3(b)(1)(ii)	<input type="checkbox"/>
Rule 15d-6	<input type="checkbox"/>
Rule 15d-22(b)	<input type="checkbox"/>

Approximate number of holders of record as of the certification or notice date: 6

Pursuant to the requirements of the Exchange Act, Forward has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Forward Pharma A/S

Date: January 17, 2023

By: /s/ Claus Bo Svendsen
Name: Claus Bo Svendsen
Title: Chief Executive Officer
